A u r a S m a r t A i r L t d .
( t h e ” C o m p a n y ” )
This is an English translation of a Hebrew report of the company, that was published on January 1, 2023 (reference No. 2023-01-000363) at the ISA reporting website (magna.isa.gov.il) (hereafter: “The Hebrew Version”). The English version is only for convenience purposes. This is not an official translation and has no binding force. The translation in any case cannot perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.
Re: Success in an experiment to destroy the RSV virus in closed spaces in a protocol
that simulates a real-life situation
The Company respectfully updates the results of an experiment to prevent the spread of the airborne RSV virus (the “virus”) in closed spaces using the Company’s unique air purification system: Aura Air (the “system”). The experiment was conducted at the Innovative Bioanalysis, Inc. laboratory facilities in California, USA (the “Laboratory”).1
The experiment’s objective was to simulate spreading the virus in a closed space via an aerosol form and determine the system’s effectiveness in purifying the virus in closed areas, proving its capability of breaking the chain of aerosol infection (the “experiment”). Below is the layout of the experimental room and the various systems as it appears in the final laboratory report:
Below is a breakdown of the experiment results:
|
Test Time |
The effectiveness of neutralizing |
|
the virus in the tested space: |
|
|
After 15 minutes |
65.56% |
|
After 30 minutes |
86.09% |
|
After 60 minutes |
99.997% |
The experiment results validate the system’s capabilities to reduce the presence of the RSV airborne virus within 60 minutes, by 99.997%, under the conditions in which the experiment was conducted. The experiment results constitute another stage in the affirmation of the system’s capabilities, joining previous studies carried out by the Sheba Medical Center, the Spanish Ministry of Defense, the Biological Institute of the Campinas University in Brazil and the laboratory (and all as detailed in Section 7.1.2 and 17 of Chapter A of the Company’s periodic report dated December 31, 2021 (reference number: 2022-01-030457) and section 7 of the corporate business update chapter in the Company’s semi-annual report dated June 30, 2022 (reference number: 2022-01-109384) regarding the effectiveness of the Company’s system in neutralizing the tested viruses. The Company intends to submit the experiment’s results for AMAR licensing (Medical Accessories and Devices) at the Israeli Ministry of Health.
About the RSV virus:
Respiratory syncytial virus (RSV) is a highly contagious virus that can cause respiratory disease in people of all ages but is especially dangerous for infants, the elderly, and people with weak immune systems. In the United States, RSV is the most common cause of
bronchiolitis (in the small airways (bronchioles) of the lung) and pneumonia in children under the age of 1 year.
According to the CDC (Center for Disease Control and Prevention), RSV is responsible for approximately 57,000 hospitalizations and 2.1 million hospital visits among children under the age of 5 in the United States each year. RSV is also a leading cause of hospitalization and mortality among adults, especially those with other underlying medical conditions.
Sincerely
Aura Smart Air Ltd.
By: Aviad Shneiderman, CEO
Disclaimer
Aura Smart Air Ltd. published this content on 03 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 January 2023 07:57:04 UTC.
Publicnow 2023
|
|
|
|
|
||||
|
||||
Income Statement Evolution
|
Sell
Buy |
|
| Mean consensus | BUY |
| Number of Analysts | 0 |
| Last Close Price | 0,45 ILS |
| Average target price | 6,70 ILS |
| Spread / Average Target | 1 396% |
[ad_2]
Originally Appeared Here